The company is running four phase 3 studies aimed at testing Vx-661/Ivacaftor in Cystic Fibrosis (CF) patients stratified by mutational status. The brokerage said Vertex's near-term catalysts are dominated by its second generation CF combination regimen of Vx-661/Ivacaftor, which Leerink regards as a $1.1 billion incremental opportunity across four CF patient groups.
"We are positive about Vx-661, and expect 3 of 4 ongoing phase III trials with Vx-661 to succeed, and show superiority to their comparator arms and to the prior precedents with Kalydeco and Orkambi in their respective indications," analyst Geoffrey Porges wrote in a note.
Meanwhile, Porges said Vx-661 should be easier to take and more effective than Orkambi and could bring revenue in the range of about $485 million, assuming comparable pricing to Orkambi in all markets.
The next catalyst for Vertex is the interim read out for the het/min study with Vx-661.
Despite the likelihood of success for the het/min study is relatively low, the analyst noted that this would potentially double the incremental revenue opportunity and value from the Vx-661 program.
At the time of writing, shares of Vertex rose 1.14 percent to $102.68. Porges has a price target of $113, implying a potential upside of 11 percent over Friday's close.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.